Flag of the European Union EU Clinical Trials Register Help

Clinical trials for Monoclonal Antibody

The European Union Clinical Trials Register   allows you to search for protocol and results information on:
  • interventional clinical trials that were approved in the European Union (EU)/European Economic Area (EEA) under the Clinical Trials Directive 2001/20/EC
  • clinical trials conducted outside the EU/EEA that are linked to European paediatric-medicine development

    • EU/EEA interventional clinical trials approved under or transitioned to the Clinical Trial Regulation 536/2014 are publicly accessible through the
    Clinical Trials Information System (CTIS).

    The EU Clinical Trials Register currently displays   43881   clinical trials with a EudraCT protocol, of which   7295   are clinical trials conducted with subjects less than 18 years old.   The register also displays information on   18700   older paediatric trials (in scope of Article 45 of the Paediatric Regulation (EC) No 1901/2006).

    Phase 1 trials conducted solely on adults and that are not part of an agreed paediatric investigation plan (PIP) are not publicly available (see Frequently Asked Questions ).  
     
    Examples: Cancer AND drug name. Pneumonia AND sponsor name.
    How to search [pdf]
    Search Tips: Under advanced search you can use filters for Country, Age Group, Gender, Trial Phase, Trial Status, Date Range, Rare Diseases and Orphan Designation. For these items you should use the filters and not add them to your search terms in the text field.
    Advanced Search: Search tools
     
    2,223 result(s) found for: Monoclonal Antibody. Displaying page 1 of 112.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    EudraCT Number: 2010-022693-14 Sponsor Protocol Number: METc2010.214 Start Date*: 2010-09-24
    Sponsor Name:university medical centre groningen
    Full Title: A study of humoral and cellular-mediated immune response in Monoclonal gammopathy of Undetermined Significance after vaccination with trivalent inactivated influenza vaccine (influvac)
    Medical condition: Monoclonal Gammopathy of Undetermined significance
    Disease: Version SOC Term Classification Code Term Level
    12.1 10027522 MGUS LLT
    12.1 10022005 Influenza viral infections HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2013-000015-24 Sponsor Protocol Number: 07MI05 Start Date*: 2015-04-10
    Sponsor Name:Great Ormond Street Hospital
    Full Title: 90-Yttrium-labelled anti-CD66 monoclonal antibody as part of a reduced intensity conditioning regimen prior to allogeneic haematopoietic stem cell transplantation: an open label, dose escalating ph...
    Medical condition: High risk relapsed or refractory leukaemia in childhood
    Disease:
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2009-011377-33 Sponsor Protocol Number: 08_CLPHA_55 Start Date*: 2009-06-25
    Sponsor Name:The Christie NHS Foundation Trust
    Full Title: AN ASSESSMENT OF IMAGING AND CIRCULATING BIOMARKERS IN PATIENTS WITH METASTATIC COLORECTAL CARCINOMA TREATED WITH THE ANTI-VEGF MONOCLONAL ANTIBODY BEVACIZUMAB
    Medical condition: Metastatic colorectal cancer
    Disease: Version SOC Term Classification Code Term Level
    14.0 10042613 - Surgical and medical procedures 10056417 Monoclonal antibody unconjugated therapy PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2012-001176-10 Sponsor Protocol Number: CNTO136ARA3004 Start Date*: 2013-09-09
    Sponsor Name:Janssen-Cilag International N.V.
    Full Title: A Multicenter, Parallel-group Study of Long-term Safety and Efficacy of CNTO 136 (sirukumab) for Rheumatoid Arthritis in Subjects Completing Treatment in Studies CNTO136ARA3002 (SIRROUND-D) and CNT...
    Medical condition: Rheumatoid Arthritis
    Disease: Version SOC Term Classification Code Term Level
    19.1 10028395 - Musculoskeletal and connective tissue disorders 10039073 Rheumatoid arthritis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: LT (Completed) ES (Completed) IT (Completed) DE (Prematurely Ended) PT (Completed) AT (Completed) GB (Completed) BE (Completed) NL (Completed) PL (Completed) HR (Completed) BG (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2011-005871-18 Sponsor Protocol Number: REDES-TNF/2012 Start Date*: 2012-04-03
    Sponsor Name:CLINICAL PHARMACOLOGY SPANISH SOCIETY
    Full Title: Evaluation of clinical value of a standardized protocol for dose reduction in patients with axial Spondyloarthritis and persistent clinical remission with anti-TNF therapy: Open-label, controlled, ...
    Medical condition: Axial Spondyloarthritis
    Disease:
    Population Age: Adults Gender: Male, Female
    Trial protocol: ES (Completed)
    Trial results: View results
    EudraCT Number: 2005-002716-16 Sponsor Protocol Number: PH-L19IL2-01/05 Start Date*: 2005-11-04
    Sponsor Name:PHILOGEN S.P.A.
    Full Title: A DOSE FINDING PHARMACOKINETIC STUDY OF THE TUMOUR TARGETING HUMAN L19IL2 MONOCLONAL ANTIBODY CYTOKINE FUSION PROTEIN IN PATIENTS WITH ADVANCED SOLID TUMOURS
    Medical condition: solid tumors and renal cell carcinoma
    Disease: Version SOC Term Classification Code Term Level
    6.1 10038408 HLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: IT (Completed)
    Trial results: (No results available)
    EudraCT Number: 2005-003132-21 Sponsor Protocol Number: EURIVAT1 Start Date*: 2005-09-28
    Sponsor Name:Dept. of Ophthalmology, Medical University of Vienna
    Full Title: European Intravitreal Avastin® Trial 1
    Medical condition: Neovascular / exudative age-related macular degeneration
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: AT (Completed)
    Trial results: View results
    EudraCT Number: 2004-004243-21 Sponsor Protocol Number: M200-1205 Start Date*: 2005-03-15
    Sponsor Name:PDL BioPharma, Inc.
    Full Title: Phase 2 Open-Label Study of Volociximab (M200) in Combination with Gemcitabine in Patients with Metastatic Pancreatic Cancer Not Previously Treated with Chemotherapy
    Medical condition: metastatic pancreatic cancer
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: (No results available)
    EudraCT Number: 2004-000039-27 Sponsor Protocol Number: MI-CP110 Start Date*: 2004-08-09
    Sponsor Name:MedImmune, Inc.
    Full Title: A pivotal phase 3 study of MEDI-524 (Numax), an enhanced potency humanized respiratory syncytial virus (RSV) monoclonal antibody, for the prophylaxis of serious RSV disease in high-risk children.
    Medical condition: Serious respiratory syncytial virus (RSV) disease
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061603
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: SE (Completed) HU (Completed) CZ (Completed) DK (Completed) IS (Completed) AT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2014-001286-28 Sponsor Protocol Number: CA209172 Start Date*: 2014-09-24
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Single-Arm, Open-Label, Multicenter Clinical Trial with Nivolumab (BMS-936558) for Subjects with Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma Progressing After Prior Tre...
    Medical condition: Histologically Confirmed Stage III (unresectable) or Stage IV Melanoma
    Disease: Version SOC Term Classification Code Term Level
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025671 Malignant melanoma stage IV PT
    19.0 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10025670 Malignant melanoma stage III PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: BE (Completed) IT (Completed) DE (Completed) GB (Completed) ES (Completed) NL (Completed) AT (Completed) DK (Completed) PT (Completed) IE (Completed) SE (Completed) FI (Completed) HU (Completed) CZ (Completed) GR (Completed) PL (Completed)
    Trial results: View results
    EudraCT Number: 2012-002767-95 Sponsor Protocol Number: 12/0161 Start Date*: 2013-06-17
    Sponsor Name:University College London
    Full Title: Long term antibody response to CMV gB vaccine in patients requiring liver or renal transplant. A Phase II open, single-site study, in participants who received CMV gB vaccine or placebo in previous...
    Medical condition: Cytomegalovirus.
    Disease: Version SOC Term Classification Code Term Level
    14.1 100000004848 10050524 Cytomegalovirus antibody LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (Completed)
    Trial results: View results
    EudraCT Number: 2011-004590-90 Sponsor Protocol Number: 3415A-001 Start Date*: 2012-02-17
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled, Adaptive Design Study of the Efficacy, Safety, and Tolerability of a Single Infusion of MK-3415 (Human Monoclonal Antibody to Clostridium ...
    Medical condition: recurrence of Clostridium difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) ES (Completed) CZ (Completed) BE (Completed) DK (Completed) PT (Completed) AT (Completed) IT (Completed) GB (Completed)
    Trial results: View results
    EudraCT Number: 2005-001671-35 Sponsor Protocol Number: MI-CP124 Start Date*: 2005-08-16
    Sponsor Name:MedImmune, Inc.
    Full Title: A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of MEDI-524, a Humanized Enhanced Potency Monoclonal Antibody Against Respiratory Syncytial Virus (RSV), in Childr...
    Medical condition: Serious respiratory syncytial virus (RSV) disease in children with hemodynamically significant congential heart disease (CHD).
    Disease: Version SOC Term Classification Code Term Level
    7.0 10061603 PT
    Population Age: Preterm newborn infants, Newborns, Infants and toddlers, Under 18 Gender: Male, Female
    Trial protocol: HU (Completed) GB (Completed) SE (Completed) CZ (Prematurely Ended) BE (Completed) DE (Completed) DK (Completed) AT (Prematurely Ended) ES (Completed) Outside EU/EEA
    Trial results: View results
    EudraCT Number: 2010-020060-38 Sponsor Protocol Number: CACZ885H2357E2 Start Date*: 2010-08-09
    Sponsor Name:Novartis Pharma Services AG
    Full Title: An open-label extension study of CACZ885H2357E1 on the treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated...
    Medical condition: Treatment and prevention of gout flares in patients with frequent flares for whom NSAIDs and/ or colchicine are contraindicated, not tolerated or ineffective
    Disease: Version SOC Term Classification Code Term Level
    12.1 10018627 Gout LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: NL (Completed)
    Trial results: View results
    EudraCT Number: 2011-004994-94 Sponsor Protocol Number: 3415A-002 Start Date*: 2011-12-21
    Sponsor Name:Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc.
    Full Title: A Phase III, Randomized, Double-Blind, Placebo-Controlled Study of the Efficacy, Safety and Tolerability of a Single Infusion of MK-6072 (Human Monoclonal Antibody to C. difficile toxin B), and MK-...
    Medical condition: Recurrence of Clostridium difficile infection (CDI)
    Disease: Version SOC Term Classification Code Term Level
    14.1 10021881 - Infections and infestations 10054236 Clostridium difficile infection PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: SE (Completed) ES (Completed) DE (Completed) CZ (Completed) FI (Completed) PL (Completed) GR (Prematurely Ended)
    Trial results: View results
    EudraCT Number: 2008-006726-34 Sponsor Protocol Number: Anti TNF- aGvHD Start Date*: 2009-02-23
    Sponsor Name:ISTITUTO GIANNINA GASLINI
    Full Title: Anti-TNF monoclonal antibody to treat acute GvHD refractary to the first line therapy with steroids
    Medical condition: Anti-TNF monoclonal antibody to treat acute GvHD refractary to the first line therapy with steroids
    Disease: Version SOC Term Classification Code Term Level
    9.1 10010162 Complications of bone marrow transplant LLT
    Population Age: Newborns, Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: IT (Ongoing)
    Trial results: (No results available)
    EudraCT Number: 2011-001066-17 Sponsor Protocol Number: CNTO1959PSO2001 Start Date*: 2012-04-10
    Sponsor Name:Janssen-Cilag International NV
    Full Title: A Phase 2 Multicenter, Randomized, Placebo- and Active-Comparator-Controlled, Dose-Ranging Trial to Evaluate CNTO 1959 for the Treatment of Subjects with Moderate to Severe Plaque-type Psoriasis (X...
    Medical condition: Moderate to Severe Plaque-type Psoriasis
    Disease: Version SOC Term Classification Code Term Level
    15.0 10040785 - Skin and subcutaneous tissue disorders 10037153 Psoriasis PT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) BE (Completed)
    Trial results: View results
    EudraCT Number: 2009-015936-14 Sponsor Protocol Number: CH14.181021 Start Date*: 2010-03-10
    Sponsor Name:University Children´s Hospital Tübingen,
    Full Title: PHASE II FEASIBILITY STUDY USING CH14.18/CHO ANTIBODY AND SUBCUTANEOUS INTERLEUKIN 2 AFTER HAPLOIDENTICAL STEM CELL TRANSPLANTATION IN CHILDREN WITH RELAPSED NEUROBLASTOMA
    Medical condition: Pediatric patients with relapsed neuroblastoma
    Disease: Version SOC Term Classification Code Term Level
    19.1 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps) 10066595 Neuroblastoma recurrent PT
    Population Age: Infants and toddlers, Children, Adolescents, Under 18 Gender: Male, Female
    Trial protocol: AT (Completed) DE (Completed)
    Trial results: View results
    EudraCT Number: 2005-003232-21 Sponsor Protocol Number: C0524T12 Start Date*: 2006-12-11
    Sponsor Name:Centocor B.V.
    Full Title: A Multicenter, Randomized, Double-blind, Placebo-controlled Trial of Golimumab, a Fully Human Anti-TNFalfa Monoclonal Antibody, Administered Intravenously, in Subjects with Active Rheumatoid Arthri...
    Medical condition: Rheumatoid Arthritis (RA)
    Disease:
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: DE (Completed) HU (Completed) LV (Completed) LT (Completed) MT (Completed)
    Trial results: View results
    EudraCT Number: 2018-000058-22 Sponsor Protocol Number: CA224-048 Start Date*: 2018-12-20
    Sponsor Name:Bristol-Myers Squibb International Corporation
    Full Title: A Phase 1/2 Study of Relatlimab (anti-LAG-3 Monoclonal Antibody) Administered in Combination with Both Nivolumab (anti-PD-1 Monoclonal Antibody) and BMS- 986205 (IDO1 inhibitor) or in Combination w...
    Medical condition: Advanced Malignant Tumors
    Disease: Version SOC Term Classification Code Term Level
    20.0 100000004864 10048683 Advanced cancer LLT
    Population Age: Adults, Elderly Gender: Male, Female
    Trial protocol: GB (GB - no longer in EU/EEA) ES (Ongoing) IT (Ongoing)
    Trial results: (No results available)
    Download Options:
    Number of Trials to download:
    Download Content:
    Download Format:
    Note, where multi-state trials are shown in search results, selecting "Full Trial details" will download full information for each of the member states/countries involved in the trial.
    1  2  3  4  5  6  7  8  9  Next» Last»»
    Query did not match any studies.
    For support, Contact us.
    The status and protocol content of GB trials is no longer updated since 1 January 2021. For the UK, as of 31 January 2021, EU Law applies only to the territory of Northern Ireland (NI) to the extent foreseen in the Protocol on Ireland/NI. Legal notice
    As of 31 January 2023, all EU/EEA initial clinical trial applications must be submitted through CTIS . Updated EudraCT trials information and information on PIP/Art 46 trials conducted exclusively in third countries continues to be submitted through EudraCT and published on this website.

    European Medicines Agency © 1995-Sun May 19 22:09:27 CEST 2024 | Domenico Scarlattilaan 6, 1083 HS Amsterdam, The Netherlands
    EMA HMA